1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. News
  7. All News
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about LIPOCINE INC.
05/12Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten..
MT
05/12LIPOCINE INC. : Financial Statements and Exhibits (form 8-K)
AQ
05/12LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/12Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
PR
05/12Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results
CI
05/09LIPOCINE : Q1 Earnings Snapshot
AQ
05/09LIPOCINE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/09LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/09Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
PR
05/09Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/25Lipocine Inc. Grants Antares Pharma an Exclusive License to Commercialize TLANDO in the..
CI
04/11LIPOCINE : ANNOUNCES BOARD of DIRECTOR APPOINTMENTS - Form 8-K
PU
04/11LIPOCINE INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
04/11LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
PR
04/11Lipocine Inc. Announces Board Appointments
CI
04/01LIPOCINE INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
03/30Lipocine announces its partner received fda approval of tlando
AQ
03/29Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy
MT
03/29LIPOCINE : ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ - Form 8-K
PU
03/29LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/29LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™
PR
03/29Lipocine Inc. Announces Its Partner Received FDA Approval of TLANDO™
CI
03/15Top Premarket Decliners
MT
03/09Earnings Flash (LPCN) LIPOCINE Posts Q4 Revenue $16.1M
MT
03/09LIPOCINE : Announces Financial Results for the Year Ended December 31, 2021 - Form 8-K
PU
03/09LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/09This annual report on form 10-k, in particular "item 7. management's discussion and ana..
AQ
03/09Lipocine Announces Financial Results for the Year Ended December 31, 2021
PR
03/09Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/07LIPOCINE : Management Change/Compensation - Form 8-K/A
PU
03/07LIPOCINE INC. Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
03/01LIPOCINE : Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH - Form 8-K
PU
03/01LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/01Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
PR
03/01Lipocine Inc. Announces Regulatory Guidance on LPCN 1144 in Non-Cirrhotic Nash
CI
02/04Lipocine announces its partner received fda acceptance of nda resubmission for tlando
AQ
02/03LIPOCINE : ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® -..
PU
02/03LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/03Lipocine announces its partner received fda acceptance of nda resubmission for tlando®
PR
02/01Clene Names Morgan Brown as Finance Chief
MT
01/28Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO
AQ
01/27LIPOCINE : Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® - Form..
PU
01/27LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/27Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®
PR
01/27Lipocine Inc. Announces Peer-Reviewed Publication of Positive Phase 3 Study Results for..
CI
01/21Lipocine Chief Financial Officer is Retiring
MT
01/21LIPOCINE INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/21Lipocine Inc. Announces CFO Changes
CI
01/21Lipocine Inc. Announces Executive Changes
CI
01/14LIPOCINE INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan..
AQ
01/05Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
PR
01/04LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021LIPOCINE : ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of l..
PU
2021LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lipocine Commences Dosing in Phase 2 Study of Liver Cirrhosis Drug
MT
2021Lipocine announces patient dosed in its phase 2 study with lpcn 1148 for management of ..
PR
2021Lipocine Inc. Announces Patient Dosed in its Phase 2 Study with LPCN 1148 for Managemen..
CI
2021LIPOCINE : Q3 Earnings Snapshot
AQ
2021Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021 - F..
PU
2021Earnings Flash (LPCN) LIPOCINE Reports Q3 Revenue $55,000
MT
2021Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2021LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lipocine's LPCN 1144 Wins US FDA Fast-Track Designation to Treat Non-Cirrhotic Non-Alco..
MT
2021Lipocine Gets FDA Fast-Track Designation for LPCN 1144 in Non-Cirrhotic NASH
DJ
2021Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-..
PU
2021LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-..
CI
2021LIPOCINE INC. : Entry into a Material Definitive Agreement, Material Modification to Right..
AQ
2021Lipocine Announces Multiple Poster Presentations At The American Association For The St..
PU
2021LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s.
AQ
2021LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO
AQ
2021LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share..
MT
2021ANTARES PHARMA : Strikes Exclusive License Agreement For Oral Testosterone Replacement The..
MT
2021LIPOCINE : AND ANTARES PHARMA ENTER INTO U.S. Licensing Agreement to Commercialize TLANDO®..
PU
1  2  3  4  5  6Next
Upcoming event on LIPOCINE INC.